BioCentury
ARTICLE | Clinical News

Subcutaneous beloranib: Additional Phase III data

April 11, 2016 7:00 AM UTC

Additional data from the double-blind, U.S. Phase III bestPWS (ZAF-311) trial in 107 patients with Prader-Willi syndrome showed that twice-weekly 1.8 and 2.4 mg doses of subcutaneous beloranib each met the secondary endpoints of reducing from baseline to week 26 mean LDL-C (16.6 and 17.8 mg/dL, respectively, vs. a gain of 1.8 mg/dL, p<0.0001 for both), total cholesterol (17.2 and 18 mg/dL, respectively, vs. a gain of 1.3 mg/dL, p<0.001 for both), leptin (20.7 and 24 ug/L, respectively, vs. a gain of 6.9 ug/L, p<0.0001 for both), CRP (56% and 53%, respectively, vs. a gain of 2.5%, p<0.0001 for both), total body mass (2.9% and 5.7%, respectively, vs. a gain of 3.4%, p<0.0001 for both) and fat mass (4.5% and 9.8%, respectively, vs. a gain of 5.9%, p<.0.0001 for both) vs. placebo. Data were presented at the Endocrine Society meeting in Boston. ...